Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Nabriva Therapeutics AG (NBRVF) had Return on Tangible Equity of 73.90% for the most recently reported fiscal quarter, ending 2023-06-30.
| Income Statement Financials | |
$2.24M |
|
$-12.06M |
|
$9.07M |
|
$-6.83M |
|
$14.27M |
|
$-12.02M |
|
$-0.04M |
|
$-12.06M |
|
$-12.06M |
|
$-12.06M |
|
$-12.06M |
|
$-12.06M |
|
$-12.06M |
|
$-12.02M |
|
$-12.01M |
|
32.31M |
|
32.31M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$9.95M |
|
$0.25M |
|
$0.63M |
|
$10.58M |
|
$26.20M |
|
$0.34M |
|
$0.70M |
|
$26.90M |
|
$-16.32M |
|
$-16.32M |
|
$-16.32M |
|
32.31M |
|
| Cash Flow Statement Financials | |
$-5.11M |
|
$-0.05M |
|
$-4.85M |
|
$12.54M |
|
$2.25M |
|
$-10.28M |
|
$1.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.38 |
|
-- |
|
-- |
|
-0.02 |
|
-0.03 |
|
-304.55% |
|
-536.07% |
|
-536.07% |
|
-- |
|
-537.76% |
|
-537.76% |
|
$-5.11M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
-- |
|
0.51 |
|
178.11 |
|
73.90% |
|
|
Return on Tangible Equity |
73.90% |
-114.03% |
|
75.50% |
|
$-0.51 |
|
$-0.16 |
|
$-0.16 |
|